Loading stock data…
CBIO
$18.07-4.30 (-19.22%)
Market ClosedLast close May 1
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Crescent Biopharma, Inc. in the Healthcare sector is trading at $18.07. The stock is currently 38% below its 52-week high of $29.00, remaining 35.3% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why CBIO maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$18.07
Potential Upside
5%
Whystock Fair Value$18.97
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to trea...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$821.86M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-75.83%
Volume
Today's trading volume
982,183
Recent News
Crescent Biopharma: Q4 Earnings Snapshot
WALTHAM, Mass. AP) — Crescent Biopharma, Inc. CBIO) on Thursday reported a loss of $92.4 million in its fourth quarter.
Huge Insider Buying in MGM and Salesforce
As the year winds down, insiders make huge buys in MGM Resorts and Salesforce. However, those were not the only notable instances of insider buying seen recently.
Crescent and Kelun-Biotech swap cancer asset rights in double deal
The partnership includes regional rights to Crescent’s bispecific antibody and Kelun’s ADC.
Praxis soars higher; Bristol Myers’ CAR-T therapy wins broader use
Praxis shares climbed another 40% on a pair of positive updates on two different drugs. Elsewhere, Bristol Myers’ Breyanzi was cleared for its fifth cancer indication and AstraZeneca expanded a rare disease deal.
Crescent Biopharma, Kelun-Biotech Biopharmaceutical Partner in Multimillion Dollar Deal to Develop Cancer Drugs
Crescent Biopharma (CBIO) and Japan's Sichuan Kelun-Biotech Biopharmaceutical said Thursday that the